Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus MEGACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELALUTIN versus MEGACE.
DELALUTIN vs MEGACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian function and reduction of sex hormone levels. It also has antineoplastic effects through interference with estrogen receptor binding and may stimulate appetite via effects on neuropeptide Y and cytokines.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
Oral: 625 mg (suspension) or 400–800 mg (tablets) once daily.
None Documented
None Documented
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Terminal elimination half-life: 70-95 hours (mean 85 hours) in chronic dosing; shorter in initial doses; clinical context: requires 3-4 weeks to reach steady state.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Primarily renal: ~75% as glucuronide conjugates and unchanged drug; biliary/fecal: ~25% as metabolites.
Category C
Category C
Progestin
Progestin